. 2021 Oct 11;39(10):1342-1360.e14.

doi: 10.1016/j.ccell.2021.07.007. Epub 2021 Aug 5.

The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer

William A Freed-Pastor¹, Laurens J Lambert², Zackery A Ely², Nimisha B Pattada³, Arjun Bhutkar³, George Eng⁴, Kim L Mercer³, Ana P Garcia³, Lin Lin³, William M Rideout 3rd³, William L Hwang⁵, Jason M Schenkel⁶, Alex M Jaeger³, Roderick T Bronson³, Peter M K Westcott³, Tyler D Hether⁷, Prajan Divakar⁷, Jason W Reeves⁷, Vikram Deshpande⁸, Toni Delorey⁹, Devan Phillips⁹, Omer H Yilmaz¹⁰, Aviv Regev¹¹, Tyler Jacks¹²

Affiliations

¹ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
² David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
³ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
⁴ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
⁵ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
⁶ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
⁷ NanoString Inc., Seattle, WA 98109, USA.
⁸ Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
⁹ Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
¹⁰ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
¹¹ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
¹² David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: tjacks@mit.edu.

PMID: 34358448
PMCID: PMC8511341
DOI: 10.1016/j.ccell.2021.07.007

The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer

William A Freed-Pastor et al. Cancer Cell. 2021.

. 2021 Oct 11;39(10):1342-1360.e14.

doi: 10.1016/j.ccell.2021.07.007. Epub 2021 Aug 5.

Authors

Affiliations

¹ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
² David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
³ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
⁴ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
⁵ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
⁶ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
⁷ NanoString Inc., Seattle, WA 98109, USA.
⁸ Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
⁹ Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
¹⁰ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
¹¹ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
¹² David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: tjacks@mit.edu.

PMID: 34358448
PMCID: PMC8511341
DOI: 10.1016/j.ccell.2021.07.007

Abstract

The CD155/TIGIT axis can be co-opted during immune evasion in chronic viral infections and cancer. Pancreatic adenocarcinoma (PDAC) is a highly lethal malignancy, and immune-based strategies to combat this disease have been largely unsuccessful to date. We corroborate prior reports that a substantial portion of PDAC harbors predicted high-affinity MHC class I-restricted neoepitopes and extend these findings to advanced/metastatic disease. Using multiple preclinical models of neoantigen-expressing PDAC, we demonstrate that intratumoral neoantigen-specific CD8⁺ T cells adopt multiple states of dysfunction, resembling those in tumor-infiltrating lymphocytes of PDAC patients. Mechanistically, genetic and/or pharmacologic modulation of the CD155/TIGIT axis was sufficient to promote immune evasion in autochthonous neoantigen-expressing PDAC. Finally, we demonstrate that the CD155/TIGIT axis is critical in maintaining immune evasion in PDAC and uncover a combination immunotherapy (TIGIT/PD-1 co-blockade plus CD40 agonism) that elicits profound anti-tumor responses in preclinical models, now poised for clinical evaluation.

Keywords: CD155; TIGIT; immune evasion; immunotherapy; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific, and a co-Founder of Dragonfly Therapeutics and T2 Biosystems. T.J. serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech, and Skyhawk Therapeutics. T.J. is also President of Break Through Cancer. His laboratory currently receives funding from Johnson & Johnson and The Lustgarten Foundation; funds from the Lustgarten Foundation supported the research described in this manuscript. A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until August 31, 2020, was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. From August 1, 2020, A.R. is an employee of Genentech, a member of the Roche Group. A.R. and Regev lab members' work was conducted at the Broad Institute, unrelated to these later affiliations. T.D.H., P.D., and J.W.R. are employees and stockholders at NanoString Technologies, Inc. None of these affiliations represent a conflict of interest with respect to the design or execution of this study or interpretation of data presented in this manuscript.

Figures

**Figure 1.. A subset of pancreatic cancer harbors predicted MHC class I-restricted neoepitopes**
(A–B) Neoepitope landscape in TCGA_PAAD (n=148) by (A) predicted affinity for MHC class I; or (B) predicted non-binder [NB] to binder [B] or strong binder [SB; <50 nM] neoepitopes. (C–D) Neoepitope landscape in DFCI-PancSeq (n=57) by (C) predicted affinity for MHC class I; or (D) predicted NB to B or NB to SB neoepitopes. See also Figure S1 and Table S1.

**Figure 2.. Neoantigen-expressing pancreatic organoids model immune clearance and immune evasion in the same tissue and antigenic context**
(A) ‘*H11-SIIN’* (top) and ‘*H11-mLAMA4’* or *‘H11-mALG8’* (bottom) genomic loci. (B) Brightfield (left) and fluorescent (right) images of KP;SIIN pancreatic organoids. (C–D) Brightfield (left) and fluorescence stereomicroscopic (right) images of 8-week [wk] tumors following orthotopic transplantation of neoantigen-expressing pancreatic organoids into (C) immune-deficient or (D) immune-competent animals. (E) Proportion of outcomes 5 wks post-orthotopic transplantation (KP [n=15]; KP;SIIN [n=45]; KP;mLAMA4 [n-25]; KP;mALG8 [n=25]). (F) Tumor/pancreas weights 8–10 wks post-orthotopic transplantation of KP;SIIN pancreatic organoids (n=5 ‘immune-deficient’; n=24 ‘N’; n=6 ‘I’, n=30 ‘P’; bar=median). (G) Flow cytometry of mScarlet (left) or surface MHC-I [H-2K^b] (right) on tumor-derived organoids from progressor (n=7) or immune-deficient (n=5) animals −/+ interferon-γ (mean +/− SD). (H) Representative images of organoid/CD8 T cell co-culture with indicated E:T ratios. Statistical analyses: (F, G) two-sided Mann-Whitney U test (n.s. P=non-significant, ** P<0.01, *** P<0.001). See also Figure S2.

**Figure 3.. T cell exhaustion typifies the neoantigen-specific TIL response in immune-evasive PDAC**
(A) Flow cytometry of neoantigen-specific (CD44^hiTetramer⁺) CD8⁺ T cells in tumor/pancreata at 9–10 wks post-initiation, (mean +/− SD). (B) Ki67⁺ of CD44^hiTetramer⁺CD8⁺ TILs from progressor tumors (mean +/− SD). (C) Inhibitory receptor (PD-1, TIGIT, TIM-3, LAG-3) co-positivity as indicated by color in CD44^hiTetramer⁺CD8⁺ TILs from KP;SIIN tumors/pancreata; (mean +/− SD). (D) Flow cytometric characterization of neoantigen-specific (CD44^hiTetramer⁺) TILs at 5 wks post-initiation, (bar=median). (E) UMAP projection of scRNA-seq of neoantigen-specific (CD8⁺CD44^hiTetramer⁺) TILs from immune-evasive tumors. (F) Heatmap of differentially expressed genes between clusters with selected genes highlighted. (G–H) UMAP projections overlaid with (G) gene module expression for “LCMV T cell exhaustion” (CM1) and “LCMV T cell chronic effector” (CM2) or (H) indicated PAGODA gene expression programs. Statistical analyses: (A,B,D) two-sided Mann-Whitney U test (n.s. P=non-significant, * P<0.05). See also Figure S3 and Table S2.

**Figure 4.. Human PDAC harbors exhausted CD8⁺ TILs**
(A–E) Flow cytometric profiling of human PDAC CD8⁺ TILs for: (A) CD45RO; (B) Inhibitory receptor (TIGIT, PD-1, TIM-3, LAG-3) co-expression; (C) TIM3⁺TCF1^lo; (D) PD-1⁺TCF1^lo and PD-1⁺TCF1^hi; or (E) HLA-DR⁺Ki67⁺CD57^neg. (F) UMAP projection of human PDAC scRNA-seq data [n=24 patients] (Peng et al., 2019). (G) Computationally sorted cell subsets and UMAP projections overlaid with indicated genes/signatures. (A–E: bar=median). See also Figure S4.

**Figure 5.. Elevated CD155 expression within the malignant compartment in murine and human PDAC**
(A–B) Immunohistochemical analysis of CD155 on (A) murine and (B) human PDAC TMAs; quantified by H-score (right). (C–D) Flow cytometry of surface (C) CD155 or (D) PD-L1 on GDO (WT, K, P, KP) or tumor-derived organoids (progressor, immune-deficient). (E–F) ECDF analysis of CD155 (*PVR*) expression in (E) TCGA_PAAD or (F) TCGA_COAD within indicated genetic cohorts. (G) CD155 (*PVR*) expression in TCGA_PAAD stratified by total neoepitope burden (high: top 25%, low: bottom 25% from Figure 1A), (bar=median). Statistical analyses: A–B: two-sided Mann-Whitney U test, C–D: Welch’s t-test, E-G: Kolmogorov-Smirnov (n.s. P=non-significant, * P<0.05); A–D,G: bar=median. See also Figure S5.

**Figure 6.. TIGIT/PD-1/CD40a combination immunotherapy elicits anti-tumor responses in immune-evasive PDAC**
(A) Waterfall plot of evaluable tumors at 4 wks of treatment. (B) Spider plots of treatment response to PD-1/CD40a (top) and TIGIT/PD-1/CD40a (bottom). (C) Representative staining of CD8α, cytokeratin 19 (CK19), CD155, and PD-L1 of responders following 4 wks of TIGIT/PD-1/CD40a. (D) Representative mfIHC with Nanostring GeoMx DSP AOIs of a responder tumor (mPR) following 4 wks of TIGIT/PD-1/CD40a. (E–F) Flow cytometric analysis of (E) CD8⁺ T cells and (F) G-MDSCs [CD45⁺CD11b⁺F4/80^lowLy6C^lowLy6G^high], (mean +/− SD). (G) Differential protein expression in ‘CD8 high’ versus ‘CD8 low’ AOIs in non-responder tumors following 4 wks of TIGIT/PD-1/CD40a. Red: FDR<0.05. Statistical analyses: (A) two-sided Mann-Whitney U test of percent change at 4 wks of therapy, (E-F) two-sided Mann-Whitney U test, (G) linear mixed effect model with Benjamini-Hochberg FDR (n.s. P=non-significant, * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001). See also Figure S6.

**Figure 7.. Elevated CD155/TIGIT signaling is sufficient to promote immune evasion in autochthonous PDAC**
(A) Lentiviral vectors to generate autochthonous neoantigen-expressing PDAC or control. (B) Retrograde pancreatic ductal instillation of lentivirus. (C–D) Brightfield (left) and fluorescence stereomicroscopic (right) images of representative 9-wk autochthonous tumors generated using mScarletSIIN in (C) CD8α-depleted or (D) immune-competent animals. (E) Proportion of animals with mScarlet-positivity as assessed by fluorescence stereomicroscopy, 9 wks post-initiation. (F) Lentiviral vectors and R26-dCas9-VPR knock-in allele used to modulate CD155 (*Pvr*) expression in autochthonous PDAC. (G) Flow cytometric assessment of surface CD155 on pancreatic organoids following transduction with indicated lentiviruses. (H) Proportion of animals with mScarlet-positivity by fluorescence stereomicroscopy at 9–12 wks post-initiation following indicated genetic or pharmacologic modulation. See also Figure S7.

See this image and copyright information in PMC

References

1. Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, et al. (2018). Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov 8, 1096–1111. - PMC - PubMed
1. Akama-Garren EH, Joshi NS, Tammela T, Chang GP, Wagner BL, Lee DY, Rideout WM, Papagiannakopoulos T, Xue W, and Jacks T (2016). A Modular Assembly Platform for Rapid Generation of DNA Constructs. Sci. Rep 6. - PMC - PubMed
1. Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, et al. (2019). MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696–701. - PMC - PubMed
1. Anderson AC, Joller N, and Kuchroo VK (2016). Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity 44, 989–1004. - PMC - PubMed
1. Andreatta M, and Nielsen M (2016). Gapped sequence alignment using artificial neural networks: Application to the MHC class i system. Bioinformatics 32, 511–517. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Medical
- MedlinePlus Health Information
Molecular Biology Databases
- NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases
Research Materials
- Addgene Non-profit plasmid repository
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer

Affiliations

The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Medical

Molecular Biology Databases

Research Materials